| Disease Site | Disease SubType | Protocol Nbr | Title & Description |
| BONE | Bone Metastases | S0702 (CTSU/SWOG) | A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with
Bone Metastases Starting Zoledronic Acid treatment. |
| BRAIN | Brain Metastases | N0574 (NCCTG) | ** LIMITED SITES ONLY** Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in Patients with One to Three Cerebral Metastases. |
| BRAIN | Glioblastoma - Recurrent | N0872 (NCCTG) | Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined with Bevacizumab in Recurrent Glioblastoma. |
| BRAIN | Glioma | E3F05 (ECOG) | ** LIMITED SITES ONLY ** Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas. |
| BRAIN | Metastatic Brain | N107C (CTSU/NCCTG) | ** LIMITED SITES ONLY** A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease. |
| BREAST | Adjuvant | 1005 (CTSU/RTOG) | **LIMITED SITES ONLY** A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer. |
| BREAST | Adjuvant | B-39 (NSABP) | **CLOSED to Accrual 12/30/06 for patients >/= 50 years of age w/ DCIS regardless of hormone recepter status; and Invasive breast cancer who meet all criteria, >/= 50 yrs old and node negative and hormone receptor postive. ** **STUDY LIMITED TO COLO SPGS, PUEBLO, RMCC THORNTON, AURORA, RMCC SKY RIDGE, PORTER, BOULDER, RMCC MIDTOWN, SWEDISH, LOVELAND, GREELEY & LITTLETON SITES ONLY** A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs. Partial Breast Irradiation (PBI) for Women with Stage 0, I or II Breast Cancer. |
| BREAST | Adjuvant | B-43 (NSABP) | A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy. |
| BREAST | Adjuvant | B-47 (NSABP) | A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer. |
| BREAST | Adjuvant | S1007 (CTSU/SWOG) | A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. |
| BREAST | Metastatic | E2108 (ECOG) | A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer. |
| BREAST | Metastatic | E3108 (ECOG) | A Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen. |
| BREAST | Metastatic | N0733 (CTSU/NCCTG) | Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 in Patients with HER2 Positive Breast Cancer Previously Treated with Trastuzumab and an Anthracyline and/or Taxane. |
| BREAST | Neo Adjuvant | 40601 (CTSU/CALGB) | Randomized Phase III Trial of Paclitaxel + Trastuzumab + Lapatinib versus Paclitaxel + Trastuzumab as Neoadjuvant Treatment of HER2-positive Primary Breast Cancer. |
| BREAST | Triple Negative | N0937 (NCCTG) | Phase II Trial of Brostallicin and Cisplatin in Patients with Metastatic Triple Negative Breast Cancer. |
| CANCER CONTROL | Breast | 97609 (CCCWF) | Impact of Genomics and Exposures on Disparities in Breast Cancer Radiosensitivity. |
| CANCER CONTROL | Breast, Prostate & Multiple Myeloma | 70604 (CTSU/CALGB) | A Randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer. |
| CANCER CONTROL | Cancer Control - Diarrhea | N08C9 (NCCTG) | Phase III, Randomized Study of Sulfasalazine versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy. |
| CANCER CONTROL | Cancer Control - Hot Flashes | N10C2 (NCCTG) | Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes. |
| CANCER CONTROL | Cancer Control - Vaginal | N10C1 (NCCTG) | Vaginal DHEA for Vaginal Symptoms: A Phase III Randomized, Double Blind, Placebo-Controlled Study. |
| CANCER CONTROL | Oral Mucositis | N09C6 (NCCTG) | Randomized Double-Blind Study of Doxepin Rinse versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy with or without Chemotherapy. |
| CANCER CONTROL (any site) | Cancer Control - Pain | N08C1 (NCCTG) | **Arms A & D are still Open. Arm B is Closed to Accrual as of 06/12/09 for Caucasians ONLY. Arm C is Closed to Accrual 11/04/11. ** Paclitaxel-Associated Acute Pain Syndrome Natural History Study. |
| CANCER CONTROL (any site) | Peripheral Neuropathy | N08CB (CTSU/NCCTG) | A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium in Two Different Versions to Prevent Oxaliplatin-Induced Sensory Neurotoxicity. |
| GASTRO-INTESTINAL | Colon | 80702 (CTSU/CALGB) | A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer. |
| GASTRO-INTESTINAL | Colon | P-5 (NSABP) | Statin Polyp Prevention Trial in Patients with Resected Colon Cancer. |
| GASTRO-INTESTINAL | Colon, Metastatic | E4203 (ECOG) | Phase II Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expression in Previously Untreated Patients with Metastatic Colorectal Cancer. |
| GASTRO-INTESTINAL | Colorectal | E7208 (ECOG) | A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B) in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy. |
| GASTRO-INTESTINAL | Colorectal - Metastatic | C80405 (CTSU/CALGB) | A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum. |
| GASTRO-INTESTINAL | Colorectal - Metastatic | N0949 (CTSU/NCCTG) | Randomized Phase III Trial of mFOLFOX7 or XELOX Plus Bevacizumab Versus 5-Fluorouracil/Leucovorin or Capecitabine Plus Bevacizumab as First-line Treatment in Elderly Patients with Metastatic Colorectal Cancer. |
| GASTRO-INTESTINAL | Esophageal | 0436 (CTSU/RTOG) | ** LIMITED SITES ONLY** A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin and Radiation for Patients with Esophageal Cancer who are Treated without Surgery. |
| GASTRO-INTESTINAL | Esophageal | 1010 (CTSU/RTOG) | **LIMITED SITES ONLY** A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma. |
| GASTRO-INTESTINAL | Esophageal | E2208 (ECOG) | Randomized Phase II Study of Paclitaxel With or Without the Anti-IGF-IR mAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients with Metastatic Esophageal or GE Junction Cancer. |
| GASTRO-INTESTINAL | Hepatocellular | E1208 (ECOG) | A Phase III Randomized Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion. |
| GASTRO-INTESTINAL | Pancreas | 0848 (CTSU/RTOG) | **LIMITED SITES ONLY** A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma. |
| GENITO-URINARY | Prostate | 0534 (CTSU/RTOG) | **LIMITED SITES ONLY** A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy. |
| GENITO-URINARY | Prostate | 0924 (CTSU/RTOG) | **LIMITED SITES ONLY** Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial. |
| GENITO-URINARY | Prostate | E2809 (ECOG) | Androgen Receptor Modulation - Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy.
|
| GENITO-URINARY | Renal | 90802 (CTSU/SWOG) | Randomized Phase III Trial Comparing Everolimus Plus Placebo versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment with Tyrosine Kinase Inhibitors. |
| GENITO-URINARY | Renal | E4805 (ECOG) | A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AVE0005 (VEGF Trap) in Patients with Metastatic Renal Cell Carcinoma.
|
| GENITO-URINARY | Renal | S0931 (CTSU/SWOG) | EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, a Phase III Study. |
| GENITO-URINARY | Transitional Cell | 90601 (CTSU/CALGB) | A Randomized Doubled-blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma (TCC). |
| GYNECOLOGIC | Endometrial | GOG-0249 (GOG) | **LIMITED SITES ONLY** Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Carcinoma. |
| GYNECOLOGIC | Ovarian | GOG-0186I (GOG) | A Randomized Phase II Evaluation of Single-Agent Bevacizumab (IND #7921) (NSC #704865) and Combination Bevacizumab with Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma. |
| GYNECOLOGIC | Ovarian | GOG-0212 (GOG) | **LIMITED PHYSICIANS ONLY** A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or CT-2103 vs No Treatment until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve A Complete Clinical Response To Primary Platinum/Taxane Chemotherapy. |
| GYNECOLOGIC | Ovarian | GOG-0213 (GOG) | A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab (NSC #704865, IND #113912) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoerimary and Fallopian Tube Cancer. |
| GYNECOLOGIC | Uterus | GOG-0250 (GOG) | A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF with Bevacizumab (NSC #704865, IND #113912) versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF with Placebo in the Treatment of Recurring Advanced Leiomyosarcoma of the Uterus. |
| HEAD & NECK | Head & Neck | 0920 (CTSU/RTOG) | ** LIMITED SITES ONLY ** A Phase III Study of Radiation Therapy (IMRT) +/- Cetuximab (C225) for Intermediate Risk Resected Head and Neck Cancer. |
| HEAD & NECK | Head & Neck | E1305 (ECOG) | A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer. |
| HEAD & NECK | Salivary Gland | 1008 (CTSU/RTOG) | **LIMITED SITES ONLY** A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors. |
| LEUKEMIA | Acute Lymphoblastic Leukemia (ALL) | 10403 (ECOG/CALGB) | An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia (ALL). |
| LEUKEMIA | CLL | E2903 (ECOG) | Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) followed by Campath-1H for Previously Treat Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia (CLL). |
| LEUKEMIA | CLL | RC0783 (MCCRC) | Randomized Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab With or Without Concurrent Avastin® for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL). |
| LEUKEMIA | Leukemia | E3903 (ECOG) | Ancillary laboratory protocol for collecting diagnostic material on patients considered for ECOG treatment trials for leukemia or related hematologic disorders.
|
| LEUKEMIA | MDS & Symptomatic Anemia | E2905 (ECOG) | Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and In Combination with Epoetin Alfa (Procrit) in Subjects with Low or Intermediate-1 Risk MDS and Symptomatic Anemia. |
| LUNG | Advanced | S0819 (CTSU/SWOG) | A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/ Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced NSCLC. |
| LUNG | Non Small Cell | E1505 (ECOG) | A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) – IIIA Non-Small Cell Lung Cancer (NSCLC). |
| LUNG | Non Small Cell | E3508 (ECOG) | A Phase II Randomized Trial of Paclitaxel, Carboplatin, Bevacizumab with or without IMC-A12 in Patients with Advanced Non-Squamous, Non-Small Cell Lung Cancer. |
| LUNG | Non Small Cell | E5508 (ECOG) | Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC. |
| LUNG | Small Cell | 30610 (CTSU/CALGB) | ** LIMITED SITES ONLY ** Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer (SCLC) also Receiving Cisplatin and Etoposide. |
| LYMPHOMA | Follicular Lymphoma | E2408 (ECOG) | A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma. |
| LYMPHOMA | Hodgkin | S0816 (CTSU/SWOG) | A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma using Early Interim FDG-PET Imaging. |
| LYMPHOMA | Large B-Cell Lymphoma | 50303 (CTSU/CALGB) | Phase III Randomized Study of R-CHOP versus Dose Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-cell Lymphomas. |
| MELANOMA | Melanoma | E1609 (ECOG) | **LIMITED PHYSICIANS** A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon Alfa-2b for Resected High-risk Melanoma. |
| MELANOMA | Metastatic Melanoma | N0879 (NCCTG) | A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, with or without Everolimus for Therapy of Metastatic Malignant Melanoma. |
| MULTIPLE SITES | Miscellaneous | S0518 (CTSU/SWOG) | Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients |
| MULTIPLE SITES | QOL | N0392 (NCCTG) | Assessment of Patient Satisfaction with Participation in Phase II/III NCCTG Clinical Trials. |
| MYELOMA | Amyloidosis | E4A08 | A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan, and Dexamethasone (BMDex) for Untreated Patients with Systemic Light-chain (AL) Amyloidosis Ineligible for Autologous Stem-cell Transplantation. |
| MYELOMA | Multiple Myeloma | E2A08 (ECOG) | A Phase II Study of Bortezomib, Liposomal Doxorubicin, Dexamethasone, and Cyclophosphamide in Patients with Multiple Myeloma Relapsing Within 12 Months of Autologous Stem Cell Transplant. |